Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Jeffrey Bradley MD
Closed to Accrual
To compare the overall survival of patients treated with high-dose versus standard-dose conformal radiation therapy in the setting of concurrent chemotherapy; To compare the overall survival of patients treated with cetuximab versus without cetuximab in the setting of concurrent chemotherapy.
NOTE: See broadcast regarding paclitaxel shortage and RTOG 0617 recommended modifications (broadcast on 9/23/11 and posted to web site on 10/26/11).
Newly diagnosed unresectable Stage III A or B non-small cell lung cancer (NSCLC); patients who present with N2 or N3 disease and an undetectable NSCLC primary tumor also are eligible; patients with supraclavicular or contralateral hilar adenopathy are ineligible.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.